DPP4 as a Potential Candidate in Cardiovascular Disease.
Si-Yu ChenXiang-Quan KongKe-Fan ZhangShuai LuoFeng WangJun-Jie ZhangPublished in: Journal of inflammation research (2022)
The rising prevalence of cardiovascular disease has become a global health concern. The occurrence of cardiovascular disease is the result of long-term interaction of many risk factors, one of which is diabetes. As a novel anti-diabetic drug, DPP4 inhibitor has been proven to be cardiovascular safe in five recently completed cardiovascular outcome trials. Accumulating studies suggest that DPP4 inhibitor has potential benefits in a variety of cardiovascular diseases, including hypertension, calcified aortic valve disease, coronary atherosclerosis, and heart failure. On the one hand, in addition to improving blood glucose control, DPP4 inhibitor is involved in controlling cardiovascular risk factors. On the other hand, DPP4 inhibitor directly regulates the occurrence and progression of cardiovascular diseases through a variety of mechanisms. In this review, we summarize the recent advances of DPP4 in cardiovascular disease, aiming to discuss DPP4 inhibitor as a potential option for cardiovascular therapy.
Keyphrases
- cardiovascular disease
- cardiovascular risk factors
- aortic valve
- risk factors
- type diabetes
- blood glucose
- heart failure
- cardiovascular events
- global health
- risk assessment
- transcatheter aortic valve replacement
- blood pressure
- coronary artery disease
- glycemic control
- human health
- emergency department
- transcatheter aortic valve implantation
- left ventricular
- metabolic syndrome
- bone marrow
- climate change
- adipose tissue
- wound healing